Sign in to view Brent V.’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Atlanta, Georgia, United States
Contact Info
Sign in to view Brent V.’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
4K followers
500+ connections
Sign in to view Brent V.’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Brent V.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Brent V.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Sign in to view Brent V.’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Websites
- Company Website
-
http://www.themedicinescompany.com
- Company Website
-
http://www.healthaffairs.com
Experience & Education
-
Vero Biotech
***** ********* ******* & *********
View Brent V.’s full experience
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View Brent V.’s full profile
Sign in
Stay updated on your professional world
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Other similar profiles
-
Andrea Ashford-Hicks
Wellesley Hills, MAConnect -
Nagendra Roy, PMP, DASM, ITIL, SAFe, CSM, MBA, OCP
Atlanta, GAConnect -
Jason Owen
Atlanta, GAConnect -
David E Stocker
Greater Seattle AreaConnect -
Namita Khanna
Marketing and Business Strategy Consultant
Orlando, FLConnect -
Bruce Phelps
President and CEO at BiotecH Pro Consulting, LLC
Clayton, CAConnect -
Adam Hammock
Lawrenceville, GAConnect -
Stephen Isaacs
Orinda, CAConnect -
Leigh Sheehy-Cunetto
Account Executive
United StatesConnect -
Jim McGorry
Hingham, MAConnect -
Kevin Stout
Executive leader with a passion for building high-performing sales teams and organizations.
Franklin, TNConnect -
Kevin Friedman, DO
Atlanta, GAConnect -
Paul Martinez
Eaton, NYConnect -
Adinda Caudle
Associate Director, Quality Compliance
Atlanta Metropolitan AreaConnect -
James Titus
Dallas, TXConnect -
Jim Robinson
Agoura Hills, CAConnect -
Scott Megaffin
New York City Metropolitan AreaConnect -
Mark C. Trudeau
Palm Coast, FLConnect -
Carl St. Bernard
Manhattan Beach, CAConnect -
Carl Will
Elyria, OHConnect
Explore more posts
-
AJMC - The American Journal of Managed Care
A panel of experts, led by Ryan Haumschild PharmD, MS, MBA, CPEL, discuss the impact chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) have on patient quality of life and explore current treatment strategies in CLL and SLL management. Watch the series here: https://bit.ly/4aXuhr2 #CancerCare
5
-
Beacon
🚀 In 2023, the ICM market soared to $149.8bn across 169 deals! As deal values climb, accurate and timely checkpoint intelligence is critical. Our 2023 Landscape Review offers precise data and exclusive insights to support your development initiatives and boost your pipeline. Summarizing highlights from the drug, trial, and commercial landscapes across 2023, this review equips you with the confidence to navigate the checkpoint space effectively. Access your copy here: https://ter.li/6j8b9p 📥 #Checkpoint #ICMs #Pharma #DrugDevelopment
3
-
Hung Trinh
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion WALTHAM, Mass.--(BUSINESS WIRE)--Apr. 29, 2024-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd. (ONO), under which ONO will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of ONO (the “Acquisition”), for a total equity value of $2.4 billion. The boards of directors of both companies have unanimously approved the transaction. Together, ONO and Deciphera will accelerate their shared vision to deliver innovative new drugs and serve patients around the world. Deciphera brings specialized research and development capabilities in kinase drug discovery, well-established commercial and sales platforms in the United States and Europe, and global clinical development capabilities. https://lnkd.in/dY_hDwFT
10
-
Targeted Oncology
Patients with CML treated with TKIs can achieve near-normal life expectancy, but managing treatment failure and intolerance requires dose adjustments and selecting TKIs based on mutation profiles and patient factors. Read more in this article from Fadi Haddad, MD, and Hagop Kantarjian, MD, of MD Anderson Cancer Center. https://lnkd.in/expFay8E
11
1 Comment -
Medical Dialogues
JnJ Seeks USFDA Approval For Tremfya For Moderately To Severely Active Crohn's Disease Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA (guselkumab) for thetreatment of adults with moderately to severely active Crohn’s disease. This marks the second submission to the FDA for TREMFYA in inflammatory bowel disease this year following an��application in March for moderately to severely active ulcerative colitis. The latest submission includes results from the Phase 3 GALAXI program, which was featured as a late-breaking oral presentation at Digestive Disease Week (DDW) 2024 last month. The GALAXI 2 and GALAXI 3 studies were the first-ever double-blind registrational head-to-head trials to demonstrate superiority versus ustekinumab in Crohn’s disease. TREMFYA successfully met the co-primary endpoints for both SC maintenance doses (200 mg every 4 weeks [q4w] and 100 mg every 8 weeks [q8w]) compared to placebo in each individual study and demonstrated superiority to ustekinumab in multiplicity-controlled endoscopic endpoints based on data pooled from both studies. David Lee #johnson&johnson #johnson&johnsonnews #USFDA #tremfya #guselkumab #crohnsdisease #inflammatoryboweldisease #ulcerativecolitis
1
-
Dóchas Life Sciences
Enhancing Breast Cancer Treatment: Expanding CDK4/6 Inhibitor Use in the Early-Stage Setting: Danielle Roman, PharmD, BCOP, discusses the efficacy and safety outcomes of CDK4/6 inhibitors in early-stage breast cancer, as well as key considerations for CDK4/6 inhibitors in this indication. #finance #pharmacy #lifesciences
-
Chemenu
BMY announced new four-year Sotyktu (deucravacitinib) data demonstrating durable response rates and consistent safety in moderate-to-severe plaque psoriasis. Deucravacitinib is a specific, oral, intracellular TYK2 inhibitor that targets immune responses driven by type 1 IFN and IL-23 that contribute to psoriasis pathogenesis, including IL-17 production and Th1/Th17 polarization. Chemenu team is always committed to developing more compounds for drug discovery. Here come the related building blocks we can provide: https://lnkd.in/gcZukP_i 👇 #Chemenu #BMY #Sotyktu #deucravacitinib #psoriasis #TYK2inhibitor #type1IFN #IL-23 #IL-17production #Th1/Th17polarization #drugdiscovery #buildingblocks
-
Market Access Today
Hormone Replacement Therapy Delay: FDA Extends Ascendis Pharma's TransCon PTH Review by Three Months Ascendis Pharma's quest for FDA approval of its hormone replacement therapy, TransCon PTH, has faced another delay, with the review period extended by three months to August 14, 2024, due to a major amendment to their application. This prolongs the approval process for treating hypoparathyroidism, a condition affecting about 70,000 people in the U.S. The announcement caused a 6% drop in Ascendis Pharma's share price. Despite this, the therapy has shown promising results in clinical trials and received marketing authorization in Europe and the UK. Ascendis Pharma CEO Jan Møller Mikkelsen affirmed their commitment to working with the FDA and maintaining access for patients in ongoing trials and expanded access programs. This follows an earlier setback in April 2023, where the FDA cited manufacturing concerns. For more details please click the link! https://lnkd.in/dYvsQNB5 #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical
5
-
OncoDaily
FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer NEJM Group American Society of Clinical Oncology (ASCO) UCLA Health Sam S. Chang, MD MBA Gene Kramolowsky Mark Gonzalgo Jeffrey Bassett https://lnkd.in/dDdbhN8R #BladderCancer #Cancer #FDA #FDAApproval #Headlines #NonMuscleInvasiveBladderCancer #OncoDaily #Oncology #TransurethralResection #DrugDevelopment
18
-
Blue Matter
The annual meeting of the American Society of Clinical Oncology (ASCO) ended this week. Members of our team were there. Here's brief summary of the key themes that stood out from the meeting >> https://lnkd.in/ePVjs2ZH Authors: Mary Lee, Shankar Sundar, & Tahel Noy #oncology #cancerresearch #biotech #pharmaceuticals #ASCO2024 #ASCO24
40
-
Dr Cristina K Chang Hiring and Interviewing
#Rezdiffra (Resmetirom) for NASH Rezdiffra, developed by #Madrigal Pharmaceuticals, is a once-daily oral selective agonist of the thyroid hormone receptor-beta (THR-β). THR-β is responsible for regulating metabolic pathways in the liver and is frequently impaired in NASH13. Patients with #NASH have reduced levels of thyroid hormone activity in the liver with resultant impaired hepatic function. The accelerated approval of Rezdiffra was based on results from the #Phase 3 #MAESTRO- NASH trial, which was recently published in the #New England Journal of Medicine. MAESTRO-NASH is an ongoing pivotal, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 1,759 patients with biopsy-confirmed NASH. Results showed 25.9% of patients in the #resmetirom 80 mg group and 29.9% of patients in the 100 mg group achieved MASH resolution with no worsening of fibrosis compared with 9.7% of those in the placebo group.
2
-
Labiotech.eu
Can BTK inhibitors tackle cancer and autoimmunity? 🤔 💊 BTK inhibitors are a class of drugs that were initially developed to control the spread of cancer. Now, they are in the running to treat a host of autoimmune diseases. Currently, Sanofi and Novartis’ drugs seem to be making progress in the clinic. 🏥 But that’s not to say that everything is going well in the field. These drugs have led to serious side effects in patients. 🤒 Read our latest article to find out more about these cancer drugs that are emerging as autoimmune therapies! 👇 https://lnkd.in/dqbBJ8nv #BTKinhibitors #cancertreatment #autoimmunetherapies #medicalresearch #drugdevelopment #healthcareadvancements InnoCare (HKEX: 09969; SSE: 688428) | Biogen | Merck | Gossamer Bio | Oncternal Therapeutics | Johnson & Johnson | AbbVie | Eli Lilly and Company | Loxo@Lilly | AstraZeneca | BeiGene
1
-
The Center for Biosimilars
Biosimilars might be the life raft you need! 🆘 Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, breaks down innovative treatments that can deliver high-quality cancer care WITHOUT breaking the bank. She discusses: *US biologics market growing 12.5% annually over the past 5 years *Biologics projected to be 55% of the top 100 medications used in the US by 2026! *Areas she focuses on to promote biosimilars in her practice *Adoption of clinical management programs *PBM contract negotiations To read the full article: https://lnkd.in/ePiXXK-q
2
-
STORM Therapeutics Limited
📰 News alert 📰 #STORM presented interim Phase 1 clinical data on its first-in-class lead product #STC15 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024! Key highlights: 📢 STC-15 was well tolerated and clinical activity was observed across the pharmacologically active dose range in advanced cancer patients 📢 Primary objectives were achieved to progress STC-15 into combination with checkpoint inhibitor combination studies Jerry McMahon, Chief Executive Officer at Storm Therapeutics, said: “This Phase 1 data, to date, demonstrates the encouraging potential of STC-15 and its ability to impact a wide range of cancers. STC-15 is showing excellent safety and pharmacologic properties as it advances further into clinical development. As part of STORM’s evolving strategy, we are expanding our studies and structuring clinical trial designs to include patients with cancers such as lung, melanoma, head and neck, and endometrial cancer in the future, and we look forward to providing further updates in due course.” Read the press release linked in the comments below to find out more about these exciting data and developments of STORM's Phase 1 clinical study! #ASCO2024 #lifesciences #biotech #drugdiscovery #research #METTL3 #METTL1 #RNA
136
3 Comments -
Moe Alsumidaie
PPD, a renowned leader in clinical research, has been honored with the prestigious CRO Leadership Award for the 13th consecutive year. This recognition underscores PPD's unwavering commitment to innovation and excellence in the industry. The company's recent panel at the Drug Information Association (DIA) emphasized the pivotal role of real-world data (RWD) and technology in expediting drug development processes. Through the convergence of RWD and cutting-edge technologies like artificial intelligence and wearable devices, PPD showcased how real-world evidence (RWE) is transforming drug development by providing crucial insights for informed decision-making. PPD's comprehensive suite of drug development services caters to pharmaceutical and biotech companies, offering integrated CRO and CDMO solutions that span the entire development journey, from molecule to medicine. The company's recognized expertise across capabilities, compatibility, expertise, quality, and reliability has solidified its position as a trusted partner in the industry. For more details on PPD's latest achievement and industry insights, click here: https://lnkd.in/gK6NGPW5 #PPD #ClinicalResearch #DrugDevelopment #CROLeadershipAward #RealWorldData #Innovation #Excellence
2
-
DelveInsight Business Research LLP
CALQUENCE (acalabrutinib) is a next-generation, selective inhibitor of BTK that binds covalently to BTK, thereby inhibiting its activity. The drug initially received accelerated approval based on overall response rate in the US in October 2017 for the treatment of adult patients with MCL who have received at least one prior therapy, and later in August 2022 received full approval for the same. Although, now AstraZeneca has been investigating CALQUENCE for earlier use in treatment. However, it is important to note that CALQUENCE is not yet approved for MCL treatment in Japan or the EU. Unlock In-Depth Expert Insights and Analysis with DelveInsight's Exclusive EHA 2024 Reporting @ https://lnkd.in/gndz94cj #CALQUENCE #acalabrutinib #BTKinhibitor #MCL #mantlecelllymphoma #cancertherapy #oncology #drugdevelopment #AstraZeneca #FDAapproval #acceleratedapproval #fullapproval #clinicaltrials #treatmentoptions #medicalresearch #JapanHealthcare #EUmedicine #hematology #cancernews #pharmaceuticalindustry
11
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More